Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Waldenstrom Macroglobulinemia 2Rectal Neoplasms 2Pancreatic Neoplasms 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Fallopian Tube Neoplasms 2Colonic Neoplasms 2Carcinoma, Ovarian Epithelial 2Unspecified Childhood Solid Tumor, Protocol Specific 1Stomach Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Intraocular Lymphoma 1Ependymoma 1Colorectal Neoplasms 1

Interventions

Carboplatin 40Paclitaxel 30Bevacizumab 16Gemcitabine 14Cyclophosphamide 14liposomal doxorubicin 13Taxes 12Topotecan 11Cisplatin 11Docetaxel 7veliparib 6pembrolizumab 6olaparib 6Doxorubicin 6Magnetic Resonance Spectroscopy 5Albumin-Bound Paclitaxel 5sargramostim 4fludarabine 4aldesleukin 4Specimen Handling 4Oxaliplatin 4Leucovorin 4Immunoglobulin G 4Filgrastim 4Drug Therapy 4Disulfides 4Biopsy 4talazoparib 3mirvetuximab soravtansine 3Radiotherapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Fallopian Tube Neoplasms × Enzyme-Linked Immunosorbent Assay × Clear all
NCT01673217 2022-08-01

Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Roswell Park Cancer Institute

Phase 1 Completed
18 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT00357448 2019-05-14

Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer

University of Washington

Phase 1 Completed
11 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡